RUNX2 and breast carcinoma: In breast cancer, ABL phosphorylates RUNX2 through direct binding, activating its expression through its SH2 domain in a kinase-activity-dependent manner, and the activation the bone morphogenetic protein (BMP)-SMAD pathway, promoting tumor cell invasion [76].